Amy Wu is a board-certified, fellowship-trained otolaryngologist and head & neck surgeon with a strong background in translational research, including NIH-funded work and publications with Nobel Laureate Roger Tsien.
She is the founder of Antelope Surgical Solutions, a clinical-stage biotech company developing the first multimodal theranostic platform that combines fluorescence-guided surgery, PET imaging, and radiotherapy into a single small molecule. The company’s lead agent, AS1986NS, has received FDA IND clearance for prostate cancer and is supported by a proprietary multichannel fluorescence imaging system designed for real-time intraoperative use.
In addition to her leadership in biotech, she founded and scaled a private surgical practice in New York City. She is recognized as a clinician-innovator operating at the intersection of surgery, medtech, and oncology.
